Last reviewed · How we verify
Toujeo SoloStar
Toujeo SoloStar is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in cells.
Toujeo SoloStar is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Toujeo SoloStar |
|---|---|
| Also known as | Glargina U300 |
| Sponsor | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Toujeo is a concentrated formulation of insulin glargine (U-300) that provides sustained, peakless insulin coverage over 24 hours. It works by mimicking endogenous insulin, activating insulin receptors on muscle, fat, and liver cells to increase glucose uptake and reduce hepatic glucose production. The U-300 concentration allows for smaller injection volumes compared to standard insulin glargine formulations.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus (PHASE4)
- Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (PHASE4)
- Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients (PHASE3)
- Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (PHASE3)
- Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. (PHASE4)
- Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
- Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: